Search research articles
Contact Us
Filters
Showing results (21-30 of 68) with videos related to
Page
of 7
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
November 30, 2002
Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[11C]rolipram and positron emission tomography
Jean N DaSilva, Celia M Lourenco, Jeffrey H Meyer, et al.
Journal of Alzheimer'S Disease : JAD
|
March 21, 2015
Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort
Mary J Savage, Daniel J Holder, Guoxin Wu, et al.
Journal of Psychiatric Research
|
September 11, 2007
Is bigger better for depression trials?
Kenneth S Liu, Duane B Snavely, William A Ball, et al.
Science Translational Medicine
|
January 8, 2024
Shifting the trajectory of therapeutic development for neurological and psychiatric disorders
Dimitri Krainc, William J Martin, Bradford Casey, et al.
The Journal of Clinical Psychiatry
|
January 14, 2003
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder
Thomas Spencer, John H Heiligenstein, Joseph Biederman, et al.
Innovations in Clinical Neuroscience
|
May 16, 2015
Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium
Jared W Young, William Z Potter, Steve Riley, et al.
Journal of Clinical Psychopharmacology
|
June 23, 2012
A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder
Lobna Ibrahim, Nancy Diaz Granados, Libby Jolkovsky, et al.
Biological Psychiatry
|
April 23, 2003
Assessing and interpreting treatment effects in longitudinal clinical trials with missing data
Craig H Mallinckrodt, Todd M Sanger, Sanjay Dubé, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
January 8, 2005
Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo
Aimee M Hunter, Andrew F Leuchter, Melinda L Morgan, et al.
The American Journal of Psychiatry
|
July 3, 2008
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia
Anantha Shekhar, William Z Potter, Jeffrey Lightfoot, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 68) with videos related to
Sort By:
Page
of 7
European Journal of Nuclear Medicine and Molecular Imaging
|
November 30, 2002
Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[11C]rolipram and positron emission tomography
Jean N DaSilva, Celia M Lourenco, Jeffrey H Meyer, et al.
Journal of Alzheimer'S Disease : JAD
|
March 21, 2015
Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort
Mary J Savage, Daniel J Holder, Guoxin Wu, et al.
Journal of Psychiatric Research
|
September 11, 2007
Is bigger better for depression trials?
Kenneth S Liu, Duane B Snavely, William A Ball, et al.
Science Translational Medicine
|
January 8, 2024
Shifting the trajectory of therapeutic development for neurological and psychiatric disorders
Dimitri Krainc, William J Martin, Bradford Casey, et al.
The Journal of Clinical Psychiatry
|
January 14, 2003
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder
Thomas Spencer, John H Heiligenstein, Joseph Biederman, et al.
Innovations in Clinical Neuroscience
|
May 16, 2015
Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium
Jared W Young, William Z Potter, Steve Riley, et al.
Journal of Clinical Psychopharmacology
|
June 23, 2012
A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder
Lobna Ibrahim, Nancy Diaz Granados, Libby Jolkovsky, et al.
Biological Psychiatry
|
April 23, 2003
Assessing and interpreting treatment effects in longitudinal clinical trials with missing data
Craig H Mallinckrodt, Todd M Sanger, Sanjay Dubé, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
January 8, 2005
Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo
Aimee M Hunter, Andrew F Leuchter, Melinda L Morgan, et al.
The American Journal of Psychiatry
|
July 3, 2008
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia
Anantha Shekhar, William Z Potter, Jeffrey Lightfoot, et al.
Page
of 7